Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
about
Beneficial autoimmunity at body surfaces - immune surveillance and rapid type 2 immunity regulate tissue homeostasis and cancerDamage-associated molecular patterns in cancer: a double-edged swordCrosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor MicroenvironmentThe ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases.Serum IL-33 level is a predictor of progression-free survival after chemotherapy.Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cellsIL-33 activates tumor stroma to promote intestinal polyposis.Interleukin-33 in Tissue Homeostasis, Injury, and InflammationThe Association of Serum IL-33 and sST2 with Breast CancerAn antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer.Evaluation of the circulating levels of IL-12 and IL-33 in patients with breast cancer: influences of the tumor stages and cytokine gene polymorphisms.Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells.The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice.Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer.The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophagesRole of IL-33 expression in oncogenesis and development of human hepatocellular carcinoma.Deletion of IL-33R attenuates VEGF expression and enhances necrosis in mammary carcinoma.Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33.Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironmentThe Role of IL-33-Dependent Inflammation in the Tumor Microenvironment.Significance of interleukin-33 and its related cytokines in patients with breast cancers.The route to pathologies in chronic inflammatory diseases characterized by T helper type 2 immune cells.Innate lymphoid cells involve in tumorigenesis.Pivotal roles of ILCs in hepatic diseases.IL‑33 restricts invasion and adhesion of trophoblast cell line JEG3 by downregulation of integrin α4β1 and CD62L.Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy.IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis.Tristetraprolin inhibits gastric cancer progression through suppression of IL-33.Interleukin 33: an innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer.Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis.IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2-ERK1/2 Pathway.Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity.Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils.IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment.Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways.IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma.Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc Min/+ mice.Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival.
P2860
Q26865509-6A00DF79-9F85-410E-A26B-09908C9B2810Q28067434-77C5EA47-476D-499E-9AFA-53C19D52785CQ28077126-E0F7102B-402F-4AED-ACC5-CCC1413BE5E9Q33593742-7A4A39B0-B3F8-4830-B091-B3493BB6C741Q33798754-24993ACE-16C5-4676-894A-2F7B352CB2A5Q34749359-2E697419-8ED2-4082-95F3-571F8FEECDCBQ35616286-1BA6671C-8D4D-4E7C-836E-278ECFC57277Q35754479-5F3FCBA7-279A-4615-9728-684E14851962Q36119005-06AD629C-F86E-4419-B0C9-BE474530B1B6Q36473012-437A95E3-84B9-4300-A3E5-4B225316A4E8Q36553112-6A906372-9036-4CDB-BC37-A2FB0A592791Q36597506-B01B08DE-6DD7-4099-AD86-20FDAD38A3D8Q36597522-E9FED004-0960-4AFE-907E-81265250A454Q36751804-57515ED9-E779-44B0-B1D2-572E1C39197AQ36876563-3F1A3DA9-13CD-45C1-ADC8-08F58B06EF56Q37001426-1567FE86-F77D-46D4-B19C-78066858FBBBQ37109698-8B2726B7-A56D-4EA4-BD05-AA02FAEC49A2Q37251140-727B3668-762F-4428-B266-A3F66FC50F8AQ37416678-B8690A97-0A76-4301-A83D-19B8FC900601Q37439634-51D33B40-8E4C-4475-BC24-3E179DD728EBQ37571181-59EA31B3-63C7-4337-A62C-68F139EC1D7FQ37700227-282F0E5E-0BA1-4101-8E1C-3E154E8B6C2DQ38224933-D7FCA077-4B14-45DD-8D69-40E98DA6CC1EQ38325566-28A7BFBC-708E-47A1-9144-477F5FC04C7BQ38366661-DB57D37D-6EF2-486C-AD9F-9206331F1690Q38695921-0DE6B9A9-C383-4F61-BB06-7D2819842EE9Q38753216-BE5F80D8-F322-46FE-8B67-347E86BED84DQ38775054-EE547541-0390-4B40-BB83-70B5A90729E6Q38778534-FF014F63-A2F6-4823-BF74-2581F62D9D55Q38783993-D5E83E8A-A093-4AF4-BAA5-5871C4439E45Q38872144-3B6F4753-BA71-4C93-A322-78BE204812E1Q38912671-676BB13C-7128-4258-9441-9EC3EE896C33Q38926338-F15E2AC3-DBDE-4753-A280-8F1547C3B32FQ39625095-9622D6E1-ED8B-400A-A040-9EAB99203C94Q40146282-AD8D45EF-5FE5-4A54-87EA-F7E3911F56CAQ40312760-14FCED32-ED80-4DC6-80BF-93495FA6763AQ40470696-AC6D3606-11DB-4546-BC92-66972D5D55CFQ40881169-35CE1B38-1A50-4BA4-9562-898147B81A09Q41019883-2BCD3C4E-62B7-4B1A-AE89-DA8BA7F89214Q41489558-9F64CD3B-B80E-46A6-8A09-016FA0C764F1
P2860
Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Interleukin-33/ST2 axis promot ...... ive and innate lymphoid cells.
@en
Interleukin-33/ST2 axis promot ...... ive and innate lymphoid cells.
@nl
type
label
Interleukin-33/ST2 axis promot ...... ive and innate lymphoid cells.
@en
Interleukin-33/ST2 axis promot ...... ive and innate lymphoid cells.
@nl
prefLabel
Interleukin-33/ST2 axis promot ...... ive and innate lymphoid cells.
@en
Interleukin-33/ST2 axis promot ...... ive and innate lymphoid cells.
@nl
P2860
P50
P356
P1476
Interleukin-33/ST2 axis promot ...... ive and innate lymphoid cells.
@en
P2093
Marija Z Milovanovic
Miodrag L Lukic
P2860
P304
P356
10.1002/IJC.28481
P577
2013-10-10T00:00:00Z